TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).

Ing Soo Tiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.